Tofogliflozin

Tofogliflozin (CSG-452) is a highly efficient and selective inhibitor of SGLT2, with Ki values of 2.9, 14.9 and 6.4nM for human, rat and mouse SGLT2 respectively.

[1]Nagata T, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol. 2013 Oct;170(3):519-31.|[2]Yamane M, et al. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobiotica. 2014 Oct 28:1-9.|[3]Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012 Jun;341(3):692-701.|[4]Nagata T, et al. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. Am J Physiol Endocrinol Metab. 2013 Feb 15;304(4):E414-23.Biochem Pharmacol. 2016 Feb 1;101:27-39. |J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Mar 15;1141:122020.|Biochem Pharmacol. 2018 Jun;152:45-59.|University of Paris. 2022 Sep 19.